Hepatocellular Carcinoma, Lenvatinib, Liver Cancer, Microwave Ablation, Recurrent Tumor
Conditions
Brief summary
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
Detailed description
Microwave ablation (MWA) is available as the major curative treatments for early-stage recurrent HCC. Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. No study has evaluated MWA simultaneously combined Lenvatinib for recurrent HCC. There needs further investigation to explore the efficacy and safety of the combination treatment. Thus, the investigators carried out this randomized, multicenter, prospective trial study to find out it.
Interventions
PROCEDUREMicrowave ablation
only microwave ablation for tumor
DRUGLenvatinib
lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma； 2. recurrent HCC without any tumor related therapy； 3. Tumor number ≤3； 4. Tumor size ≤5cm; 5. Good performance, KPS≥90； 6. Age：18-75 7. Child-Pugh A or B（score of the B level is no more than 7） 8. Baseline laboratory examinations meet the Criteria： Leukocyte ≥3.0×109/L； Blood platelet ≥75×109/L； Hemoglobin ≥100g/L； ALT、AST ≤ 3 x limit of normal（ULN）； Serum creatinine ≤ 1.5 x ULN； Prothrombin time \< ULN+4 s；INR \< 1.5, Albumin ≥30g/L ； Total bilirubin ≤34mmol/L；
Exclusion criteria
1. disagreeing to receive follow-up observation and participate the clinical study; 2. Accompanying with a history of other malignancies; 3. Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus; 4. with extrahepatic metastasis or lymph metastasis; 5. receiving system therapy such as targeted therapy or immunotherapy; 6. receiving local therapy such as ablation or TACE; 7. Any of the following occurred within 12 months of the study: myocardial infarction, severe / unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), pulmonary embolism; ongoing arrhythmia by NCI-CTCA standard ≥ 2, prolonged QTc interval (450 ms for males, and\> 470 ms for females; 8. other serious acute, chronic physiological or mental disorders or abnormal laboratory examination may increase the risk of participation in study treatment or may interfere with the interpretation of study findings or whom the investigator considers not fit;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor-free survival rate at 36 months | 36 months | Progression was defined as progressive disease after microwave ablation by independent radiologic review according to mRECIST or death from any cause |
| Over-all survival (OS) rate at 36 months | 36 months | OS is the length of time from the date of microwave ablation until death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 24 months | Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report. |
| Complication rate | 36 months | Complication was defined as the a disease or sythrome caused by the therapy |
Countries
China
Contacts
Primary ContactQunfnag Zhou, MD
Backup ContactXiaohui Wang, MD
Outcome results
None listed